BioXcel Therapeutics
BTAI
BTAI
73 hedge funds and large institutions have $28.2M invested in BioXcel Therapeutics in 2023 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 23 increasing their positions, 27 reducing their positions, and 24 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
49% less call options, than puts
Call options by funds: $776K | Put options by funds: $1.51M
50% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 24
Holders
73
Holding in Top 10
–
Calls
$776K
Puts
$1.51M
Top Buyers
| 1 | +$783K | |
| 2 | +$532K | |
| 3 | +$322K | |
| 4 |
PI
Pennant Investors
Summit,
New Jersey
|
+$248K |
| 5 |
BlackRock
New York
|
+$226K |
Top Sellers
| 1 | -$1.09M | |
| 2 | -$537K | |
| 3 | -$387K | |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$376K |
| 5 |
Goldman Sachs
New York
|
-$335K |